Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SLC9A3 | P48764 | 5/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067044 | 0.86 | MEN1 (0.37) | MEN1KMT2ATSHRSLC9A3RECQL | |
| SCHEMBL20067051 | 0.85 | MEN1 (0.36) | MEN1KMT2ATSHRSLC9A3RECQL | |
| SCHEMBL20077542 | 0.83 | MEN1 (0.34) | MEN1KMT2ATSHRSLC9A3RECQL | |
| SCHEMBL20067053 | 0.82 | MEN1 (0.40) | MEN1KMT2ATSHRRECQLCA12 | |
| SCHEMBL20067046 | 0.77 | CASP2 (0.37) | MEN1KMT2ATSHRRECQL | |
| SCHEMBL20067054 | 0.76 | KMT2A (0.48) | MEN1KMT2ATSHRRECQLCA12 | |
| SCHEMBL20067037 | 0.75 | BLM (0.35) | TSHRCHRM2CA12CA1CA2 | |
| SCHEMBL20067035 | 0.75 | DNM1 (0.36) | — | |
| SCHEMBL12423819 | 0.75 | KMT2A (0.47) | MEN1KMT2ATSHRRECQLCA12 | |
| SCHEMBL20067042 | 0.73 | MEN1 (0.42) | MEN1KMT2ATSHRRECQLCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180108944-A1 | GRAPHENE COMPOUND AND MANUFACTURING METHOD THEREOF, ELECTROLYTE, AND POWER STORAGE DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180108944-A1 | GRAPHENE COMPOUND AND MANUFACTURING METHOD THEREOF, ELECTROLYTE, AND POWER STORAGE DEVICE | ILK, GK, KCNH3 | MEN1 4232/4885KMT2A 1311/4885TSHR 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.